Counterfeit Weight Loss Drug Floods Black Market While Still in Trials

A surge of counterfeit versions of an investigational drug has been reported on the black market, according to industry sources and law‑enforcement agencies. The drug, currently in Phase III clinical trials for a rare neurological disorder, has attracted attention from unscrupulous distributors who are exploiting its growing reputation and the high demand for unapproved therapies.

The counterfeit products are being sold in a variety of formats, including capsules and liquid preparations, and are marketed as the genuine investigational agent. Early laboratory analyses suggest that the active ingredient is either absent or present in sub‑therapeutic quantities, raising concerns about potential harm to consumers who may be unaware of the fraud. Regulatory bodies are coordinating with customs and border‑control authorities to trace the supply chain and to prevent further circulation of these illicit products.

Authorities have urged the public to verify the authenticity of any medication through official channels and to report suspicious purchases. The pharmaceutical company behind the trial has issued a statement confirming that it has not approved the drug for commercial sale and that any unauthorized distribution is illegal. Investigations are ongoing to identify the sources of the counterfeit supply and to strengthen safeguards around the distribution of investigational therapies.